BRONCHOGEN 20MG

Bronchogen 20mg is a synthetic tetrapeptide bioregulator with the amino acid sequence Ala-Glu-Asp-Leu (AEDL), developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. As the dedicated pulmonary member of the Khavinson bioregulator family, Bronchogen is studied for its tissue-specific regulatory activity in bronchial epithelial cells and alveolar type II pneumocytes — the two primary cell populations governing airway barrier integrity and surfactant production in the respiratory system.

Research into Bronchogen centers on its proposed ability to penetrate bronchial epithelial cell nuclei and bind to specific DNA promoter regions, modulating gene expression programs governing epithelial differentiation, mucin production (MUC4, MUC5AC), surfactant protein expression (SFTPA1, NKX2-1), and inflammatory cytokine regulation. Published preclinical studies — including Kuzubova et al. (Bulletin of Experimental Biology and Medicine, 2015) — have documented Bronchogen’s effects on epithelial cell proliferation, regenerative capacity, and anti-inflammatory signaling in obstructive lung pathology models. A 2020 Khavinson review also discussed Bronchogen alongside Chonluten as bronchial epithelium-protective compounds relevant to viral respiratory injury research.

Beyond Health Lab supplies Bronchogen 20mg as a research-grade lyophilized compound, HPLC-verified for 99% purity, shipped within 24 hours from Mexico.

For research use only. Not intended for human or animal consumption.

FAQ:

What is Bronchogen and what respiratory cells does it target?
Bronchogen (AEDL) is a Khavinson tetrapeptide bioregulator specifically developed for research into bronchial and pulmonary tissue. It targets bronchial epithelial cells and alveolar type II pneumocytes — the cells responsible for airway barrier function and surfactant synthesis respectively. Its proposed epigenetic mechanism involves direct DNA binding in respiratory cell nuclei to modulate tissue-specific gene expression, distinguishing it from bronchodilators or anti-inflammatory compounds that act through receptor pathways.

What specific genes and pathways has Bronchogen been studied for in preclinical models?
Research has documented Bronchogen’s effects on MUC4 and MUC5AC mucin gene expression, SFTPA1 and NKX2-1 surfactant protein genes, epithelial differentiation and regeneration markers, and pro-inflammatory cytokine signaling pathways in bronchial cell cultures and animal models of obstructive lung pathology. Key published references include Kuzubova et al. (2015) and Titova et al. (2017), both examining antiinflammatory and regenerative effects in COPD models.

How does Bronchogen compare to other Khavinson respiratory bioregulators like Chonluten?
Within the Khavinson respiratory bioregulator research space, Bronchogen (AEDL) targets the bronchial epithelium and airways, while Chonluten targets bronchopulmonary tissue with overlapping but distinct gene targets. The two are frequently studied in combination in comprehensive respiratory aging research panels. Bronchogen’s particular strength in published literature is its documented effects on epithelial cell regeneration and barrier function in obstructive pathology models.

How should Bronchogen 20mg be stored?
Store lyophilized Bronchogen at 2–8°C away from light and moisture. Once reconstituted with bacteriostatic water, keep refrigerated and use within 28 days for optimal stability and research-grade performance.